News Website

Retraction Note: The comparison of two different protocols ultra-long versus medroxyprogesterone acetate in women with ovarian endometriosis: a prospective randomized controlled trial - Reproductive Health

Retraction Note: The comparison of two different protocols ultra-long versus medroxyprogesterone acetate in women with ovarian endometriosis: a prospective randomized controlled trial Reproductive Health

Published: March 9, 2025, 9:57 p.m.

Read Full Article

Endothelial senescence induced by PAI-1 promotes endometrial fibrosis - Nature.com

Endothelial senescence induced by PAI-1 promotes endometrial fibrosis Nature.com

Published: March 6, 2025, 5:36 p.m.

Read Full Article

The Prognostic Value of Maximum Standardized Uptake Value (SUVmax) of 18F-FDG PET/CT for Risk Stratification and Outcome Prediction in Endometrial Cancer: A Retrospective Analysis - Cureus

The Prognostic Value of Maximum Standardized Uptake Value (SUVmax) of 18F-FDG PET/CT for Risk Stratification and Outcome Prediction in Endometrial Cancer: A Retrospective Analysis Cureus

Published: March 6, 2025, 1:45 a.m.

Read Full Article

Long-Term Outcomes of Robotic-Assisted Laparoscopy - Physician's Weekly

Long-Term Outcomes of Robotic-Assisted Laparoscopy Physician's Weekly

Published: March 4, 2025, 12:07 p.m.

Read Full Article

Virgo: Your career horoscope - March 01 - MSN

Virgo: Your career horoscope - March 01 MSN

Published: March 1, 2025, 11:36 p.m.

Read Full Article

Virgo: Monthly horoscope March - MSN

Virgo: Monthly horoscope March MSN

Published: March 1, 2025, 10:35 a.m.

Read Full Article

Characteristics of Patients Undergoing Laparoscopic Hysterectomy for Atypical Endometrial Hyperplasia - Cureus

Characteristics of Patients Undergoing Laparoscopic Hysterectomy for Atypical Endometrial Hyperplasia Cureus

Published: March 1, 2025, 5:24 a.m.

Read Full Article

Sure, Sheargold’s opinions are sexist dross. But we’re missing the real point - Sydney Morning Herald

Sure, Sheargold’s opinions are sexist dross. But we’re missing the real point Sydney Morning Herald

Published: Feb. 28, 2025, 12:30 a.m.

Read Full Article

Karyopharm targets $1B revenue potential for Selinexor in myelofibrosis amid Phase 3 progress - MSN

Karyopharm targets $1B revenue potential for Selinexor in myelofibrosis amid Phase 3 progress MSN

Published: Feb. 21, 2025, 12:07 p.m.

Read Full Article

Figure 3: Gross examination of specimen showing poorly circumscribed... - ResearchGate

Figure 3: Gross examination of specimen showing poorly circumscribed... ResearchGate

Published: Feb. 18, 2025, 9:34 a.m.

Read Full Article

Latest Articles

Retraction Note: The comparison of two different protocols ultra-long versus medroxyprogesterone acetate in women with ovarian endometriosis: a prospective randomized controlled trial - Reproductive Health

Endothelial senescence induced by PAI-1 promotes endometrial fibrosis - Nature.com

The Prognostic Value of Maximum Standardized Uptake Value (SUVmax) of 18F-FDG PET/CT for Risk Stratification and Outcome Prediction in Endometrial Cancer: A Retrospective Analysis - Cureus

Long-Term Outcomes of Robotic-Assisted Laparoscopy - Physician's Weekly

Virgo: Your career horoscope - March 01 - MSN

Virgo: Monthly horoscope March - MSN

Characteristics of Patients Undergoing Laparoscopic Hysterectomy for Atypical Endometrial Hyperplasia - Cureus

Sure, Sheargold’s opinions are sexist dross. But we’re missing the real point - Sydney Morning Herald

Karyopharm targets $1B revenue potential for Selinexor in myelofibrosis amid Phase 3 progress - MSN

Figure 3: Gross examination of specimen showing poorly circumscribed... - ResearchGate

Subscribe to Our Newsletter